(Q38570326)

4 September 2017

Appropriate models for novel osteoporosis drug discovery and future perspectives (English)

1 reference

4 September 2017

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Luigi Gennari

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Stefano Rotatori

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Simone Bianciardi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Stefano Gonnelli

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Ranuccio Nuti

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

21 August 2015

1 reference

Expert Opinion on Drug Discovery

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

1201-1216

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

Epidemiology and outcomes of osteoporotic fractures

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone remodelling: its local regulation and the emergence of bone fragility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone quality--the material and structural basis of bone strength and fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteocyte-driven bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Pathogenesis of osteoporosis: concepts, conflicts, and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Choosing between predictors of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteoporosis: now and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Status of drug development for the prevention and treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Models and screening assays for drug discovery in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Effects of calcitonin on animal and in vitro models of skeletal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Mechanisms by which high-dose estrogen therapy produces anabolic skeletal effects in postmenopausal women: role of locally produced growth factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Sex steroids and the construction and conservation of the adult skeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Estrogen plus progestin and the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

An overview of current and emerging SERMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Tissue-selective estrogen complexes for postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bisphosphonates: the first 40 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Biochemical and molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Benefits and risks of bisphosphonate therapy for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Anabolic effect of low doses of a fragment of human parathyroid hormone on the skeleton in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Mechanisms of anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Investigational anabolic therapies for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

New renal anemia drugs: is there really anything new on the horizon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

The RANKL inhibitor OPG-Fc increases cortical and trabecular bone mass in young gonad-intact cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Effect of odanacatib on bone turnover markers, bone density and geometry of the spine and hip of ovariectomized monkeys: a head-to-head comparison with alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

High bone density due to a mutation in LDL-receptor-related protein 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Wnt signaling and osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Targeting sclerostin as potential treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Bone metabolism and histomorphometric changes in murine models treated with sclerostin antibody: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Romosozumab in postmenopausal women with low bone mineral density.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Novel techniques in the development of osteoporosis drug therapy: the osteoclast ruffled-border vacuolar H(+)-ATPase as an emerging target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

MicroRNA functions in osteogenesis and dysfunctions in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

RNA therapeutics targeting osteoclast-mediated excessive bone resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Developing siRNA therapies to address osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Proteomics in bone research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Therapeutic application of mesenchymal stem cells in bone and joint diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Targeting integrins to promote bone formation and repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

A review of rodent models of type 2 diabetic skeletal fragility

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Treat-to-target for osteoporosis: is now the time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

Odanacatib in the treatment of postmenopausal women with low bone mineral density: Three-year continued therapy and resolution of effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2015.1080685

10.1517/17460441.2015.1080685

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26292627%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

1 reference